

ARIKAYCE
(amikacin liposome inhalation suspension)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Mycobacterium avium complex (MAC) lung disease

AND ALL of the following:

1. Diagnosis has been confirmed by at least 2 sputum cultures
2. Inadequate treatment response to at least 6 consecutive months of a multidrug regimen
3. Alternative treatment options have been ruled out
4. Culture shows that the MAC isolate is susceptible to amikacin with a minimum inhibitory concentration (MIC) of ≤ 64 mcg/mL
5. Arikayce will be given with other antibacterial drugs
6. Patients with a history of hyperactive airway disease will pre-treat with an inhaled bronchodilator
7. Prescriber agrees to monitor for respiratory adverse reactions
8. Pregnant patients and female patients of reproductive potential will be advised of the potential adverse effects to the fetus

Prior - Approval Limits

Quantity 84 vials* per 84 days

Duration 168 days

*Vials supplied with Lamira Nebulizer System

Prior – Approval *Renewal* Requirements

Age 18 years of age and older

Diagnosis



**BlueCross
BlueShield**

Federal Employee Program.

ARIKAYCE
(amikacin liposome inhalation suspension)

Patient must have the following:

Mycobacterium avium complex (MAC) lung disease

AND ALL of the following:

1. Patient has not achieved consecutive monthly negative sputum cultures in 6 months
2. Arikayce will be given with other antibacterial drugs
3. Patients with a history of hyperactive airway disease will pre-treat with an inhaled bronchodilator
4. Prescriber agrees to monitor for respiratory adverse reactions
5. Pregnant patients and female patients of reproductive potential will be advised of the potential adverse effects to the fetus

Prior - Approval *Renewal* Limits

Quantity 196 vials

Duration 196 days (One renewal only)